Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lanyan Fang

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Journal of Clinical Pharmacology|May 16, 2019
Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case StudySarah Kim, Vishnu D Sharma, Karthik Lingineni, et al.
Journal of Clinical Pharmacology|January 25, 2007
Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patientsLanyan Fang, Nicholas H G Holford, George Hinkle, et al.
The AAPS Journal|August 28, 2014
A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II designJoanna Z Peng, William S Denney, Bret J Musser, et al.
Clinical Pharmacology and Therapeutics|February 8, 2022
Considerations for the Forced Expiratory Volume in 1 Second-Based Comparative Clinical Endpoint Bioequivalence Studies for Orally Inhaled Drug ProductsJieon Lee, Kairui Feng, Denise S Conti, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 19, 2022
Regulatory utility of physiologically-based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary reportFang Wu, Youssef Mousa, Kimberly Raines, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 30, 2023
Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products: Summary of workshopYuqing Gong, Peijue Zhang, Miyoung Yoon, et al.
Advanced Drug Delivery Reviews|August 29, 2022
Scientific and regulatory activities initiated by the U.S. food and drug administration to foster approvals of generic dry powder inhalers: Quality perspectiveNashwa El-Gendy, Craig M Bertha, Mohammed Abd El-Shafy, et al.
Advanced Drug Delivery Reviews|September 6, 2022
Scientific and regulatory activities initiated by the U.S. Food and drug administration to foster approvals of generic dry powder inhalers: Bioequivalence perspectiveBryan Newman, Andrew Babiskin, Elizabeth Bielski, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 17, 2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity ScoresCameron D Thomas, Scott A Mosley, Sarah Kim, et al.
Molecular Pharmaceutics|September 30, 2024
PBBM Considerations for Base Models, Model Validation, and Application Steps: Workshop Summary ReportTycho Heimbach, Flora Musuamba Tshinanu, Kimberly Raines, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Journal of Clinical Pharmacology|May 16, 2019
Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case StudySarah Kim, Vishnu D Sharma, Karthik Lingineni, et al.
Journal of Clinical Pharmacology|January 25, 2007
Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patientsLanyan Fang, Nicholas H G Holford, George Hinkle, et al.
The AAPS Journal|August 28, 2014
A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II designJoanna Z Peng, William S Denney, Bret J Musser, et al.
Clinical Pharmacology and Therapeutics|February 8, 2022
Considerations for the Forced Expiratory Volume in 1 Second-Based Comparative Clinical Endpoint Bioequivalence Studies for Orally Inhaled Drug ProductsJieon Lee, Kairui Feng, Denise S Conti, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 19, 2022
Regulatory utility of physiologically-based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary reportFang Wu, Youssef Mousa, Kimberly Raines, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 30, 2023
Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products: Summary of workshopYuqing Gong, Peijue Zhang, Miyoung Yoon, et al.
Advanced Drug Delivery Reviews|August 29, 2022
Scientific and regulatory activities initiated by the U.S. food and drug administration to foster approvals of generic dry powder inhalers: Quality perspectiveNashwa El-Gendy, Craig M Bertha, Mohammed Abd El-Shafy, et al.
Advanced Drug Delivery Reviews|September 6, 2022
Scientific and regulatory activities initiated by the U.S. Food and drug administration to foster approvals of generic dry powder inhalers: Bioequivalence perspectiveBryan Newman, Andrew Babiskin, Elizabeth Bielski, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 17, 2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity ScoresCameron D Thomas, Scott A Mosley, Sarah Kim, et al.
Molecular Pharmaceutics|September 30, 2024
PBBM Considerations for Base Models, Model Validation, and Application Steps: Workshop Summary ReportTycho Heimbach, Flora Musuamba Tshinanu, Kimberly Raines, et al.
Pageof 7